Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent plasma therapy in hospitalized patients with COVID-19
IRCT20150808023559N21Phase 2Completed
- Sponsor
- Ardabil University of Medical Sciences
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Ardabil University of Medical Sciences. Primary endpoints: All-cause mortality reduction and Hospital stay reduction. Started May 2020; status: completed.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20150808023559N21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150808023559N21.